Drug General Information (ID: DDI4FBUXD3)
Drug Name			Zidovudine		Drug Info		Peginterferon beta-1a		Drug Info
Drug Type		Small molecule				Interferons
Therapeutic Class		Anti-Hiv Agents				Interferons

Mechanism of Zidovudine-Peginterferon beta-1a Interaction (Severity Level: Major)
Additive myelosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Zidovudine				Peginterferon beta-1a
Mechanism		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 1
		Factor Name		Myelosuppressive effects
		Factor Description		Myelosuppression, also known as bone marrow suppression, is a decrease in bone marrow activity that leads to a decrease in the production of blood cells. Some blood cell disorders include: erythrocytopenia (anemia), leukopenia (neutropenia), and thrombocytopenia (thrombocytopenia).
Mechanism Description		Additive myelosuppressive effects by the combination of Zidovudine and Peginterferon beta-1a

Recommended Action
Management		Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons. Complete blood counts, differential and platelet counts should be performed regularly and drug dosages adjusted accordingly. Patients should be advised to promptly report symptoms such as chills, fever, sore throat, pale skin, or unusual fatigue to their physician. Cessation of one or all drugs may be necessary if toxicity develops.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Intron A (interferon alfa-2b). Schering Laboratories, Kenilworth, NJ.
3	Nokta M, Loh JP, Douidar SM, Ahmed AE, Pollard RB "Metabolic interaction of recombinant interferon-beta and zidovudine in AIDS patients." J Interferon Res 11 (1991): 159-64.[PMID: 1919075]